Showing results (1481-1490 of 8,878) with videos related to

Sort By:
Pageof 888
BJU International|September 22, 2011
Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trialTruls E Bjerklund Johansen, Timothy M Baker, Libby K Black
BJU International|September 22, 2011
Predictors of locally advanced and metastatic disease in patients with small renal massesMax Kates, Ruslan Korets, Neda Sadeghi, et al.
BJU International|September 22, 2011
Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancerEinar Servoll, Thorstein Saeter, Ljiljana Vlatkovic, et al.
BJU International|September 22, 2011
Compliance with biopsy recommendations of a prostate cancer risk calculatorHeidi A van Vugt, Monique J Roobol, Martijn Busstra, et al.
BJU International|June 4, 2011
Consumerism and its impact on robotic-assisted radical prostatectomySultan Alkhateeb, Nathan Lawrentschuk
BJU International|June 4, 2011
Twenty-year prevalence of diabetes mellitus and hypertension in patients receiving shock-wave lithotripsy for urolithiasisBen H Chew, Bogard Zavaglia, Christine Sutton, et al.
BJU International|May 24, 2011
Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasisKouji Izumi, Atsushi Mizokami, Shingo Itai, et al.
BJU International|May 24, 2011
How often are patients with diabetes or hypertension being treated with partial nephrectomy for renal cell carcinoma? A population-based analysisRobert Abouassaly, Antonio Finelli, George A Tomlinson, et al.
BJU International|February 1, 2012
Different surgical findings in congenital and acquired undescended testesJocelyn van Brakel, Gert R Dohle, Sabine M P F de Muinck Keizer-Schrama, et al.
BJU International|February 16, 2012
The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mLNicola L Dallas, Peter R Malone, Adam Jones, et al.
Pageof 888